Dr Ceri Fielding

2022

• Fielding, C. A. et al. 2022. SARS-CoV-2 host-shutoff impacts innate NK cell functions, but antibody-dependent NK activity is strongly activated through non-spike antibodies. eLife 11 (10.7554/eLife.74489)
• Wang, E. C., Fielding, C. A. and Stanton, R. J. 2022. Concerns over functional experiments, interpretation, and required controls. Journal of Clinical Investigation 132(5), article number: e157369. (10.1172/JCI157369)
• Nightingale, K. et al. 2022. Human cytomegalovirus protein RL1 degrades the antiviral factor SLFN11 via recruitment of the CRL4 E3 ubiquitin ligase complex. Proceedings of the National Academy of Sciences 119(6), article number: e2108173119. (10.1073/pnas.2108173119)

2020

• Elasifer, H. et al. 2020. Downregulation of HLA-I by the molluscum contagiosum virus mc080 impacts NK-cell recognition and promotes CD8+ T-cell evasion. Journal of General Virology 101, pp. 863-872. (10.1099/jgv.0.001417)

2018

• Patel, M., Vlachava, V., Forbes, S. K., Fielding, C. A., Stanton, R. J. and Wang, E. 2018. HCMV-encoded NK modulators: Lessons from in vitro and in vivo genetic variation. Frontiers in Immunology 9, article number: 2214. (10.3389/fimmu.2018.02214)
• Nightingale, K. et al. 2018. High-definition analysis of host protein stability during human cytomegalovirus infection reveals antiviral factors and viral evasion mechanisms. Cell Host and Microbe 24(3), pp. 447-460.e11. (10.1016/j.chom.2018.07.011)
• Wang, E. C. Y. et al. 2018. Suppression of costimulation by human cytomegalovirus promotes evasion of cellular immune defenses. Proceedings of the National Academy of Sciences 115(19), pp. 4998-5003. (10.1073/pnas.1720950115)

2017

• Stacey, M. A. et al. 2017. The antiviral restriction factor IFN-induced transmembrane protein 3 prevents cytokine-driven CMV pathogenesis. Journal of Clinical Investigation 127(4), pp. 1463-1474. (10.1172/JCI84889)
• Fielding, C. A. et al. 2017. Control of immune ligands by members of a cytomegalovirus gene expansion suppresses natural killer cell activation. eLife 6, article number: e22206. (10.7554/eLife.22206)

2016

• Murrell, I. et al. 2016. Genetic stability of BAC-deerived human cytomegalovirus during culture in vitro. Journal of Virology 90(8), pp. 3929-3943. (10.1128/JVI.02858-15)

2015

• Wilkinson, G. W. G. et al. 2015. Human cytomegalovirus: taking the strain. Medical Microbiology and Immunology 204(3), pp. 273-284. (10.1007/s00430-015-0411-4)
• Fielding, C. A. 2015. Mimicry of cytokine pathways by human herpesviruses. Future Virology 10(1), pp. 41-51. (10.2217/fvl.14.101)

2014

• Weekes, M. et al. 2014. Quantitative temporal viromics: an approach to investigate host-pathogen interaction. Cell 157(6), pp. 1460-1472. (10.1016/j.cell.2014.04.028)
• Fielding, C. A. et al. 2014. Two novel human cytomegalovirus NK cell evasion functions target MICA for lysosomal degradation. PLoS Pathogens 10(5), article number: e1004058. (10.1371/journal.ppat.1004058)
• Seirafian, S., Prod'homme, V., Sugrue, D., Davies, J., Fielding, C., Tomasec, P. and Wilkinson, G. W. G. 2014. Human cytomegalovirus suppresses Fas expression and function. Journal of General Virology 95(4), pp. 933-939. (10.1099/vir.0.058313-0)
• Jones, S. A., Fraser, D. J., Fielding, C. A. and Jones, G. W. 2014. Interleukin-6 in renal disease and therapy. Nephrology Dialysis Transplantation 30(4), pp. 564-574. (10.1093/ndt/gfu233)
• Fielding, C. A. et al. 2014. Interleukin-6 signaling drives fibrosis in unresolved inflammation. Immunity 40(1), pp. 40-50. (10.1016/j.immuni.2013.10.022)

2013

• Lauder, S. N. et al. 2013. Interleukin-6 limits influenza-induced inflammation and protects against fatal lung pathology. European Journal of Immunology 43(10), pp. 2613-2625. (10.1002/eji.201243018)
• Fielding, C. A., Jones, G. W., Taylor, P. R., Jenkins, B. J., Topley, N. and Jones, S. A. 2013. IL-6 regulation of Th1 responses drives fibrosis in unresolved inflammation [Abstract]. Cytokine 63(3), pp. 262. (10.1016/j.cyto.2013.06.082)

2012

• Pembroke, T. et al. 2012. Rapid early innate control of hepatitis C virus during IFN-α treatment compromises adaptive CD4+T-cell immunity. European Journal of Immunology 42(9), pp. 2383-2394. (10.1002/eji.201142072)
• Fielding, C. A. et al. 2012. A novel human cytomegalovirus gene function targets the natural killer cell activating ligand MICA for lysosomal degradation [Abstract]. Immunology 137(S1), pp. 154. (10.1111/imm.12001)
• Fielding, C. A. 2012. Interleukin-19: a new target to aim for?. Rheumatology 51(3), pp. 399-400. (10.1093/rheumatology/ker174)

2011

• Colmont, C. S. et al. 2011. Human peritoneal mesothelial cells respond to bacterial ligands through a specific subset of Toll-like receptors. Nephrology Dialysis Transplantation 26(12), pp. 4079-4090. (10.1093/ndt/gfr217)

2010

• Lin, C. et al. 2010. The HMB-PP producing capacity of the causative pathogen and local gamma delta T cell numbers predict clinical outcome from bacterial peritonitis. Immunology 131, pp. 81-82.
• Stumhofer, J. S. et al. 2010. A role for IL-27p28 as an antagonist of gp130-mediated signaling. Nature Immunology 11(12), pp. 1119-1126. (10.1038/ni.1957)
• Lauder, S. N., Smart, K., Ondondo, B., Fielding, C. A., Godkin, A. J., Jones, S. A. and Gallimore, A. M. 2010. A critical role for interleukin-6 in limiting influenza-induced pathology and generating heterosubtypic immunity [Abstract]. Immunology 131(S1), pp. 186. (10.1111/j.1365-2567.2010.03390.x)
• Coles, B., Colmont, C. S., Fielding, C. A., Kift-Morgan, A., Hams, E., Topley, N. and Jones, S. A. 2010. Local manipulation of IL-6 trans-signaling therapeutically enhances anti-microbial host defense [Abstract]. Cytokine 52(1-2), pp. 80-81. (10.1016/j.cyto.2010.07.335)
• Li, N., McLaren, J. E., Michael, D. R., Clement, M., Fielding, C. A. and Ramji, D. P. 2010. ERK is integral to the IFN-γ-mediated activation of STAT1, the expression of key genes implicated in atherosclerosis, and the uptake of modified lipoproteins by human macrophages. The Journal of Immunology 185(5), pp. 3041-3048. (10.4049/jimmunol.1000993)

2009

• Luo, D. D., Fielding, C. A., Phillips, A. O. and Fraser, D. J. 2009. Interleukin-1 beta regulates proximal tubular cell transforming growth factor beta-1 signalling. Nephrology Dialysis Transplantation 24(9), pp. 2655-2665. (10.1093/ndt/gfp208)

2008

• Rabe, B. et al. 2008. The role of IL6-transsignaling in acute and chronic inflammation [Abstract]. Cytokine 43(3), pp. 244-244. (10.1016/j.cyto.2008.07.073)
• Jenkins, B. J. et al. 2008. Differential roles of IL-6 and IL-11 in inflammation and tumorigenesis [Abstract]. Cytokine 43(3), pp. 243-243. (10.1016/j.cyto.2008.07.069)
• Hams, E. et al. 2008. Oncostatin M receptor-β signaling limits monocytic cell recruitment in acute inflammation. Journal of Immunology 181(3), pp. 2174-2180.
• Fielding, C. A. et al. 2008. IL-6 regulates neutrophil trafficking during acute inflammation via STAT3. Journal of Immunology 181(3), pp. 2189-2195.
• Hams, E. et al. 2008. Oncostatin M receptor-beta signaling limits monocytic cell recruitment in acute inflammation. Journal of Immunology 181(3), pp. 2174-2180.
• Fielding, C. A. and Topley, N. 2008. Piece by piece: solving the puzzle of peritoneal fibrosis [Commentary]. Peritoneal Dialysis International 28(5), pp. 477-479.

2007

• Chalaris, A. et al. 2007. Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils. Blood -New York- 110(6), pp. 1748-1755. (10.1182/blood-2007-01-067918)
• Rabe, B. et al. 2007. IL6/sIL6R-transsignaling controls innate and aquired immunity [Abstract]. Cytokine 39(1), pp. 34-34. (10.1016/j.cyto.2007.07.129)
• Hams, E. et al. 2007. Oncostatin M receptor signalling regulates monocytic cell trafficking during acute inflammation [Abstract]. Cytokine 39(1), pp. 14-14. (10.1016/j.cyto.2007.07.053)
• Coles, B., Fielding, C. A., Rose-John, S., Scheller, J., Jones, S. A. and O'Donnell, V. B. 2007. Classic interleukin-6 receptor signaling and interleukin-6 trans-signaling differentially control angiotensin II-dependent hypertension, cardiac signal transducer and activator of transcription-3 activation, and vascular hypertrophy in vivo. American Journal of Pathology 171(1), pp. 315-325. (10.2353/ajpath.2007.061078)

2006

• Nowell, M. A. et al. 2006. Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis. Arthritis & Rheumatism 54(7), pp. 2084-2095. (10.1002/art.21942)
• Monslow, J. et al. 2006. Sp1 and Sp3 mediate constitutive transcription of the human hyaluronan synthase 2 gene. The Journal of Biological Chemistry 281(26), pp. 18043-18050. (10.1074/jbc.M510467200)
• Osborne, C. S., Leitner, I., Hofbauer, B., Fielding, C. A., Favre, B. and Ryder, N. S. 2006. Biological, biochemical, and molecular characterization of a new clinical Trichophyton rubrum isolate resistant to terbinafine. Antimicrobial Agents and Chemotherapy 50(6), pp. 2234-2236. (10.1128/AAC.01600-05)
• Richards, P. J. et al. 2006. Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis. Arthritis & Rheumatism 54(5), pp. 1662-1672. (10.1002/art.21818)

2005

• Fielding, C. A. et al. 2005. Viral IL-6 blocks neutrophil infiltration during acute inflammation. The Journal of Immunology 175(6), pp. 4024-4029.
• Siebert, S., Fielding, C. A., Williams, B. D. and Brennan, P. 2005. Mutation of the extracellular domain of tumour necrosis factor receptor 1 causes reduced NF‐κB activation due to decreased surface expression. FEBS Letters 579(23), pp. 5193-5198. (10.1016/j.febslet.2005.08.037)
• McLoughlin, R. M. et al. 2005. IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. Proceedings of the National Academy of Sciences of the United States of America (PNAS) ISSN 1091-6490 102(27), pp. 9589-9594. (10.1073/pnas.0501794102)
• Siebert, S., Amos, N., Fielding, C. A., Wang, E. C. Y., Aksentijevich, I., Williams, B. D. and Brennan, P. 2005. Reduced tumor necrosis factor signaling in primary human fibroblasts containing a tumor necrosis factor receptor superfamily 1A mutant. Arthritis & Rheumatism 52(4), pp. 1287-1282. (10.1002/art.20955)

2004

• Fielding, C. A., Siebert, S., Rowe, M. and Brennan, P. 2004. Analysis of human tumour necrosis factor receptor 1 dominant-negative mutants reveals a major region controlling cell surface expression. FEBS Letters 570(1-3), pp. 138-142. (10.1016/j.febslet.2004.06.035)

2003

• Richardson, C. J., Fielding, C., Rowe, M. and Brennan, P. 2003. Epstein-Barr virus regulates STAT1 through latent membrane protein 1. Journal of Virology 77(7), pp. 4439-4443. (10.1128/JVI.77.7.4439-4443.2003)

2001

• Fielding, C. A., Sandvej, K., Mehl, A. M., Brennan, P., Jones, M. and Rowe, M. 2001. Epstein-Barr virus LMP-1 natural sequence variants differ in their potential to activate cellular signaling pathways. Journal of Virology 75(19), pp. 9129-9141. (10.1128/JVI.75.19.9129-9141.2001)